Pacira pain drug succeeds in late-stage trial
Feb 27 (Reuters) - Pacira Pharmaceuticals Inc said a late-stage trial testing its drug Exparel for a wider use showed the treatment significantly reduced pain compared to placebo in knee surgery patients.
Exparel is already approved for use in managing post-surgical pain when administered directly at the site of the pain. The latest trial was testing Exparel's efficacy when applied to a major nerve adjacent to the site of the surgery, thereby blocking any sensation until the nerve endings.
A late-stage trial testing the drug, Exparel, showed that patients taking the medicine experienced significant reduction in pain over 72 hours.
- U.S. air strikes on Syria would face formidable obstacles
- Samsung unveils smartwatch that can make calls
- Russian-backed separatists enter southeast Ukraine town
- FBI, Secret Service investigate reports of cyber attacks on U.S. banks
- Breakthrough hopes dented as Ukraine accuses Russia of new incursion |